company background image
PUR

Pure Biologics Spólka Akcyjna WSE:PUR Stock Report

Last Price

zł43.80

Market Cap

zł98.7m

7D

-7.6%

1Y

-55.4%

Updated

15 May, 2022

Data

Company Financials +
PUR fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

PUR Stock Overview

Pure Biologics Spólka Akcyjna, a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare diseases.

Pure Biologics Spólka Akcyjna Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Pure Biologics Spólka Akcyjna
Historical stock prices
Current Share Pricezł43.80
52 Week Highzł118.60
52 Week Lowzł39.40
Beta1.44
1 Month Change-21.79%
3 Month Change-37.61%
1 Year Change-55.40%
3 Year Change28.07%
5 Year Changen/a
Change since IPO91.27%

Recent News & Updates

Apr 30
Will Pure Biologics Spólka Akcyjna (WSE:PUR) Spend Its Cash Wisely?

Will Pure Biologics Spólka Akcyjna (WSE:PUR) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Jan 03
We Think Pure Biologics Spólka Akcyjna (WSE:PUR) Can Afford To Drive Business Growth

We Think Pure Biologics Spólka Akcyjna (WSE:PUR) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Apr 21
We're Interested To See How Pure Biologics Spólka Akcyjna (WSE:PUR) Uses Its Cash Hoard To Grow

We're Interested To See How Pure Biologics Spólka Akcyjna (WSE:PUR) Uses Its Cash Hoard To Grow

We can readily understand why investors are attracted to unprofitable companies. For example, Pure Biologics Spólka...

Shareholder Returns

PURPL BiotechsPL Market
7D-7.6%1.5%-0.3%
1Y-55.4%-37.7%-14.4%

Return vs Industry: PUR underperformed the Polish Biotechs industry which returned -37.7% over the past year.

Return vs Market: PUR underperformed the Polish Market which returned -14.4% over the past year.

Price Volatility

Is PUR's price volatile compared to industry and market?
PUR volatility
PUR Average Weekly Movement8.6%
Biotechs Industry Average Movement8.8%
Market Average Movement7.6%
10% most volatile stocks in PL Market14.4%
10% least volatile stocks in PL Market5.1%

Stable Share Price: PUR is not significantly more volatile than the rest of Polish stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: PUR's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201096n/ahttps://www.purebiologics.com

Pure Biologics Spólka Akcyjna, a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use.

Pure Biologics Spólka Akcyjna Fundamentals Summary

How do Pure Biologics Spólka Akcyjna's earnings and revenue compare to its market cap?
PUR fundamental statistics
Market Capzł98.73m
Earnings (TTM)-zł11.76m
Revenue (TTM)zł18.03m

5.5x

P/S Ratio

-8.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PUR income statement (TTM)
Revenuezł18.03m
Cost of Revenuezł28.49m
Gross Profit-zł10.46m
Other Expenseszł1.31m
Earnings-zł11.76m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

May 16, 2022

Earnings per share (EPS)-5.22
Gross Margin-58.00%
Net Profit Margin-65.24%
Debt/Equity Ratio0%

How did PUR perform over the long term?

See historical performance and comparison

Valuation

Is Pure Biologics Spólka Akcyjna undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


2.5x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PUR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PUR's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: PUR is unprofitable, so we can't compare its PE Ratio to the Polish Biotechs industry average.

PE vs Market: PUR is unprofitable, so we can't compare its PE Ratio to the Polish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PUR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PUR is good value based on its PB Ratio (2.5x) compared to the PL Biotechs industry average (6.2x).


Future Growth

How is Pure Biologics Spólka Akcyjna forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


19.8%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if PUR's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if PUR's earnings are forecast to grow faster than the Polish market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PUR's revenue (19.8% per year) is forecast to grow faster than the Polish market (6.3% per year).

High Growth Revenue: PUR's revenue (19.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PUR's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Pure Biologics Spólka Akcyjna performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-56.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PUR is currently unprofitable.

Growing Profit Margin: PUR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PUR is unprofitable, and losses have increased over the past 5 years at a rate of 56.5% per year.

Accelerating Growth: Unable to compare PUR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PUR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.9%).


Return on Equity

High ROE: PUR has a negative Return on Equity (-29.8%), as it is currently unprofitable.


Financial Health

How is Pure Biologics Spólka Akcyjna's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PUR's short term assets (PLN43.0M) exceed its short term liabilities (PLN5.5M).

Long Term Liabilities: PUR's short term assets (PLN43.0M) exceed its long term liabilities (PLN2.2M).


Debt to Equity History and Analysis

Debt Level: PUR is debt free.

Reducing Debt: PUR has no debt compared to 5 years ago when its debt to equity ratio was 0.1%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PUR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PUR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 37.1% each year


Dividend

What is Pure Biologics Spólka Akcyjna current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PUR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PUR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PUR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PUR's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PUR has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Pure Biologics Spólka Akcyjna has no CEO, or we have no data on them.


Leadership Team

Experienced Management: PUR's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Pure Biologics Spólka Akcyjna's employee growth, exchange listings and data sources


Key Information

  • Name: Pure Biologics Spólka Akcyjna
  • Ticker: PUR
  • Exchange: WSE
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: zł98.725m
  • Shares outstanding: 2.25m
  • Website: https://www.purebiologics.com

Number of Employees


Location

  • Pure Biologics Spólka Akcyjna
  • ul. Dunska 11
  • Wroclaw
  • 54-427
  • Poland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/13 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.